

APPENDIX TABLE. AVERAGE MONTHLY USE AND ANNUALIZED MONTHLY GROWTH RATES OF GLITAZONES.

	Glitazones		Rosiglitazone		Pioglitazone	
	Level [†] (95% CI)	Annualized Growth Rate [‡] (95% CI)	Level [†] (95% CI)	Annualized Growth Rate [‡] (95% CI)	Level [†] (95% CI)	Annualized Growth Rate [‡] (95% CI)
Jan, 2003 – Jan, 2005	779 (740 - 818)	22.0 (19.2 - 24.9)**	432 (400 - 465)	31.5 (23.9 - 39.1)**	347 (338 - 356)	13.8 (8.0 - 19.6)**
Feb, 2005 – Jan, 2007	929 (919 - 940)	-2.2 (-4.1 - -0.3)*	461 (445 - 478)	-15.5 (-20.2 - -10.7)**	468 (453 - 483)	13.7 (9.2 - 18.3)**
Feb, 2007 – May, 2008	721 (668 - 774)	-28.7 (-30.9 - -26.5)**	226 (175 - 277)	-60.2 (-63.9 - -56.4)**	495 (487 - 503)	-8.6 (-16.9 - -0.3)*
June, 2008 – June, 2009	577 (570 - 583)	-1.8 (-8.8 - 5.2)	135 (129 - 142)	10.7 (-1.7 - 23.1)	441 (433 - 450)	-7.1 (-22.6 - 8.5)

[†]Treatment Visits Levels are in thousands [‡]Figures are annualized monthly growth rates over pre-defined segments. ** significant at 1% and * significant at 5%.
Source: IMS Health, National Disease and Therapeutic Index™, 2003-2009